High‐grade B‐cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements were rare in the NPS, which is clinically relevant because these lymphomas have a poor prognosis.24 This evidence concerns the gene BCL2 and B-cell non-Hodgkin lymphoma.